On April 28, 2021 Clovis Oncology, Inc. (Nasdaq: CLVS) reported that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the Bank of America 2021 Health Care Conference on Tuesday, May 11, 2021, at 5:00 p.m. Eastern time (Press release, Clovis Oncology, APR 28, 2021, View Source [SID1234578632]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This conference is virtual and a live webcast of the presentation can be accessed through the investor relations section of the Company’s website at www.clovisoncology.com. Following the live presentation, a replay of the webcast will be available on the Company’s website for 30 days.

On April 28, 2021 Seven and Eight Biopharmaceuticals Inc., a clinical stage biotechnology company focused on developing proprietary novel immuno-oncology therapies to activate the immune system against cancer, reported the acceptance of an abstract for a poster discussion presentation at the 2021 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (Press release, Seven and Eight Biopharmaceuticals, APR 28, 2021, View Source [SID1234578631]). The abstract details additional interim safety and efficacy results for a phase 1 study of BDB001, an intravenously administered toll-like receptor 7 and 8 (TLR7/8) agonist, in combination with pembrolizumab in advanced solid tumors (NCT03486301).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to share additional information about BDB001 in combination with pembrolizumab at the 2021 ASCO (Free ASCO Whitepaper) Annual Meeting," said Dr. Robert H.I. Andtbacka, Chief Medical Officer, Seven and Eight Biopharma. "This builds upon the promising monotherapy data we reported on recently and helps illustrate the potential for BDB001 in combination with anti-PD-(L)1 therapies in difficult to treat tumors."

The ASCO (Free ASCO Whitepaper) Annual Meeting will be held virtually on June 4-8, 2021 and showcases innovative scientific research in clinical oncology and advancements in cancer therapy.

Details on Seven and Eight Biopharma’s poster discussion presentation:

Abstract Title: BDB001, an intravenously administered toll-like receptor 7 and 8 (TLR7/8) agonist, in combination with pembrolizumab in advanced solid tumors: Phase 1 safety and efficacy results.

Session Title: Poster Discussion Session, Developmental Therapeutics—Immunotherapy

On-Demand Session Release Date and Time: 6/4/2021, 9:00 AM-10:00 AM

Abstract Number for Publication: 2512

This year, ASCO (Free ASCO Whitepaper) reviewed more than 5,400 abstracts for the 2021 ASCO (Free ASCO Whitepaper) Annual Meeting. More information about the meeting may be accessed at View Source According to ASCO (Free ASCO Whitepaper)’s Embargo Policy, abstracts will be released to the public on ASCO (Free ASCO Whitepaper)’s Meeting Library at 5:00 p.m. ET on May 19, 2021.

On April 28, 2021 Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, reported that Emil Kakkis, M.D., Ph.D., will present at the 7TH Annual Truist Securities Life Sciences Summit on Wednesday, May 5, 2021 at 1:00 PM ET (Press release, Ultragenyx Pharmaceutical, APR 28, 2021, View Source [SID1234578630]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live and archived webcast of the presentation will be accessible from the company’s website at View Source The replay of the webcast will be available for 90 days.

On April 28, 2021 MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR), a commercial-stage biopharmaceutical company and a leader in antibody, protein and peptide technologies, reported that it will publish its results for the first quarter of 2021 on May 5, 2021 at 10:00pm CEST (4:00pm EDT) (Press release, MorphoSys, APR 28, 2021, View Source [SID1234578629]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MorphoSys’ Management Board will host a conference call and webcast on May 6, 2021 at 2:00pm CEST (8:00am EDT) to present the first quarter and first 3-month financial results 2021 and provide an outlook for 2021.

The conference call will start with a presentation by the Management Board followed by a Q&A session. Following Board Members will be on the call:

On April 28, 2021 CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, reported that it will present a Trials in Progress poster presentation at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (ASCO) (Free ASCO Whitepaper), to be held in a virtual format from June 4 to 8, 2021 (Press release, CRISPR Therapeutics, APR 28, 2021, View Source [SID1234578628]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Trials in Progress poster presentation will summarize the study design for the Company’s ongoing Phase 1 CARBON trial assessing the safety and efficacy of several dose levels of CTX110, its wholly-owned allogeneic CAR-T investigational therapy targeting CD19, for the treatment of relapsed or refractory B-cell malignancies.

Title: A phase 1 dose escalation and cohort expansion study of the safety and efficacy of allogeneic CRISPR-Cas9–engineered T cells (CTX110) in patients (Pts) with relapsed or refractory (R/R) B-cell malignancies (CARBON).
Session Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Abstract Number: TPS7570, e-poster
Date and Time: Friday, June 4, 2021 at 9:00 AM ET via the ASCO (Free ASCO Whitepaper) website, View Source

About CTX110
CTX110, a wholly owned program of CRISPR Therapeutics, is a healthy donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19, or CD19. CTX110 is being investigated in the ongoing CARBON trial.